Recent Agreements Set To Bolster BioNTech SE (BNTX)’s Oncology Arm

BioNTech SE (NASDAQ:BNTX) is one of the 13 Best German Stocks to Invest in Now. It is a clinical-stage biotechnology company focused on immunotherapies to treat cancer and other serious diseases.

Recent Agreements Set To Bolster BioNTech SE (BNTX)'s Oncology Arm

A microbiologist observing a petri dish of bacteria under a microscope.

On June 2, the company announced that it had agreed with Bristol Myers Squibb for the global joint development and commercialization of BioNTech SE (NASDAQ:BNTX)’s investigational bispecific antibody BNT327 for solid tumor types.

Under the terms of the agreement, Bristol Myers Squibb will pay BioNTech SE (NASDAQ:BNTX) up to $11.1 billion for the partnership, including $3.5 billion in unconditional payments.

The deal reflects the German company’s ambition to continue a costly, long-term focus on cancer treatments, and shows that its collaboration with Pfizer for the COVID-19 vaccine was not a singular achievement.

Later in the month, on June 12, BioNTech SE (NASDAQ:BNTX) announced that it would acquire CureVac for approximately $1.25 billion in shares, which is expected to further strengthen the company’s research, development, and commercialization of mRNA-based cancer treatments.

While we acknowledge the risk and potential of BNTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BNTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy and 13 Best Big Name Stocks to Buy Now.

Disclosure: None.